NCT00302497Unknown3 期
12 Month, Prospective, Randomised, Open-Label Comparative Study to Evaluate the Protection of Kidney Function by Basiliximab in a CNI-Free Regimen in Newly Kidney Transplanted Patients (Three Months Post-Transplant) Who Are Recipient of One Kidney From Expanded Donor Criteria (UNOS Criteria)
McGill University Health Centre/Research Institute of the McGill University Health Centre2 个研究点 分布在 1 个国家目标入组 50 人开始时间: 2007年4月1日最近更新:
适应症
相关药物
试验速览
- 阶段
- 3 期
- 发起方
- 入组人数
- 50
- 试验地点
- 2
- 主要终点
- To compare the annualised change in GFR (delta GFR) at three and twelve months after baseline.
研究概览
简要总结
The long-term use of calcineurin inhibitors in the maintenance phase after kidney transplantation is associated with typical adverse effects, such as potential contribution to progressive impairment of renal function, hypertension, and metabolic abnormalities.
This 15 month study with a safety follow up is undertaken to evaluate the potential benefit of an alternative treatment strategy to the chronic use of CNI. It will establish, through a comparative design, the superior protection of kidney function provided by chronic usage of basiliximab over tacrolimus early post-transplantation using EDC kidneys.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 40 Years 至 75 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •male or female patients aged 40 to 75 years with a viable graft
- •patients who are recipients of a primary or secondary graft from a cadaveric expanded donor criteria
- •patients who had no change of immunosuppressor two weeks prior to baseline
- •patients who had no acute rejection four weeks prior to baseline
- •patients who are willing and capable of giving written informed consent for study participation
- •females of childbearing potential must have a negative serum pregnancy test within 7 days prior to baseline.Effective contraception must be used during the trial and for 6 weeks following discontinuation of the study medication, even where there has been a history of infertility
- •Patients who are HCV and HBV negative
排除标准
- •patients who have a calculated GFR (Nankivell formula) of less than 30mL/min at baseline
- •Patients who are recipients of multiple organ transplants
- •Patients who are recipients of dual kidney transplants
- •Patients with panel reactive antibodies >50% at transplant
- •Patients with a known hypersensitivity to tacrolimus,EC-MPS or basiliximab at baseline
- •Patients with a known malignancy or a history of malignancy, other than successfully treated non-metastatic basal or squamous cell carcinoma of the skin
- •Patients who are HIV positive at study entry
- •Patients who have received a kidney from a HCV positive or HBV positive donor
- •Patients with signs of active immune process on graft biopsy at baseline
- •Patients with polyoma (BK or JC)
- •Patients with operative or technical failure
- •Exclusion Criteria:
结局指标
主要结局
To compare the annualised change in GFR (delta GFR) at three and twelve months after baseline.
次要结局
- To demonstrate that the efficacy of basiliximab compared to the efficacy of tacrolimus kis comparable in the prevention of acute cellular rejection at 3 and 12 months after baseline.
研究者
研究点 (2)
Loading locations...
相似试验
终止
4 期
Comparison of CNI-based Regimen Versus CNI-free Regimen in Kidney Transplant Recipients.Renal TransplantationNCT00332839Novartis Pharmaceuticals93
已完成
4 期
Safety and Efficacy of Basiliximab in Calcineurin Inhibitor Intolerant Long-term Kidney Transplant Recipients Treated With Mycophenolic Acid and SteroidsKidney TransplantationAdverse EffectsNCT00284947Novartis7
Unknown
3 期
CNI Transient Replacement by Belatacept From 3 to 12 Months Post Transplantation in Patients With Early Graft DysfunctionChronic Kidney FailureNCT04013620Nantes University Hospital48
招募中
3 期
Belatacept as a Replacement for CNIs 3 to 12 Months Post-transplantation in Patients With Early Graft DysfunctionChronic Kidney FailureNCT05562869Nantes University Hospital30
终止
1 期
Early Conversion From Tacrolimus to Efalizumab Maintenance Therapy in Kidney Transplant RecipientsKidney TransplantationChronic Kidney FailureNCT00472082Emory University5